セフチゾキシム
セフチゾキシム 物理性質(zhì)
- 融點(diǎn) :
- 227° (dec)
- 比重(密度) :
- 1.89±0.1 g/cm3(Predicted)
- 貯蔵溫度 :
- under inert gas (nitrogen or Argon) at 2–8 °C
- 溶解性:
- Aqueous Base (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated, Sonicated)
- 外見(jiàn) :
- 個(gè)體
- 酸解離定數(shù)(Pka):
- pKa 2.1 (Uncertain)
- 色:
- 白色～淡黃色
- Merck :
- 14,1951
- 安定性：:
- 吸濕性
- InChIKey:
- NNULBSISHYWZJU-LLKWHZGFSA-N
- SMILES:
- N12[C@@]([H])([C@H](NC(/C(/C3=CSC(N)=N3)=N\OC)=O)C1=O)SCC=C2C(O)=O
- CAS データベース:
- 68401-81-0(CAS DataBase Reference)
| メーカー |
製品番號(hào) |
製品説明 |
CAS番號(hào) |
包裝 |
価格 |
更新時(shí)間 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01COBQH-5417 |
セフチゾオキシム
Ceftizoxime |
68401-81-0 |
1g |
￥35000 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01COBQH-5417 |
セフチゾオキシム
Ceftizoxime |
68401-81-0 |
5g |
￥105000 |
2024-03-01 |
購(gòu)入 |
|
東京化成工業(yè)
|
C2622 |
セフチゾキシム >98.0%(HPLC)(T)
Ceftizoxime
>98.0%(HPLC)(T) |
68401-81-0 |
1g |
￥12800 |
2024-03-01 |
購(gòu)入 |
|
東京化成工業(yè)
|
C2622 |
セフチゾキシム >98.0%(HPLC)(T)
Ceftizoxime
>98.0%(HPLC)(T) |
68401-81-0 |
5g |
￥42100 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
46511-1A |
Ceftizoxime |
68401-81-0 |
1g |
￥15620 |
2024-07-01 |
購(gòu)入 |
セフチゾキシム 化學(xué)特性,用途語(yǔ),生産方法
外観
白色～ほとんど白色粉末～結(jié)晶
効能
抗生物質(zhì), 細(xì)胞壁合成阻害薬
説明
In ceftizoxime, the whole C-3 side chain has been omitted to prevent deactivation by hydrolysis. It rather
resembles cefotaxime in its properties; however, not being subject to metabolism, its pharmacokinetic
properties are much less complex.
使用
Ceftizoxime is used for bacterial infections of the lower respiratory tract, infections of the
urinary tract, infections of the bones, joints, skin, soft tissues, and abdominal infections.
Synonyms of this drug are ceftix and eposerin.
定義
ChEBI: A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position.
抗菌性
A semisynthetic cephalosporin supplied as the sodium salt. The
properties are very similar to those of cefotaxime, but it lacks
the acetoxymethyl group at position C-4 and is therefore not
subject to deacetylation. Activity against common pathogenic
bacteria (Table 13.4) is very similar to that of cefotaxime.
A 500 mg intramuscular injection achieves a plasma concentration
of around 14 mg/L. A concentration of 85–90 mg/L
is produced 30 min at the end of a 30-min intravenous infusion.
The plasma half-life is 1.3–1.9 h. Protein binding is
30%. It is well distributed. In children with meningitis receiving
200–250 mg/kg per day in four equally divided doses for
14–21 days, mean CSF concentrations 2 h after a dose were
6.4 mg/L on day 2 and 3.6 mg/L on day 14.
About 70–90% of the dose is recovered in the urine in the first
24 h, principally by glomerular filtration. Probenecid increases
the plasma half-life by about 50%. In patients receiving 1 g
intravenously over 30 min, the plasma elimination half-life rose
to 35 h when the corrected creatinine clearance was <10 mL/
min. It is partly removed by peritoneal and hemodialysis.
Adverse reactions and clinical use are similar to those of
cefotaxime.
セフチゾキシム 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品
セフチゾキシム 生産企業(yè)
Global( 244)Suppliers
68401-81-0(セフチゾキシム)キーワード:
- 68401-81-0
- (6R,7R)-7α-[2-(2-Imino-4-thiazolin-4-yl)-2-[(Z)-methoxyimino]acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Ceftizox
- (7R)-7-[[2-(2-Aminothiazole-4-yl)-2-(methoxyimino)-1-oxoethyl]amino]cepham-3-ene-4-carboxylic acid
- (7R)-7β-[2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetylamino]cepham-3-ene-4-carboxylic acid
- Ceftizoxime (350 mg)I0E2620.999mg/mg(an)
- Ceftizoxime (350 mg)
- (6R,7R)-7-[(2Z)-2-(2-aMino-1,3-thiazol-4-yl)-2-(MethoxyiMino)acetaMido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- EPOCELIN
- CEFTIZOXIME
- CEFTIZOXIME ACID
- (6r-(6-alpha,7-beta(z)))-l)(methoxyimino)acetyl)amino)-8-oxo
- 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-(((2-amino-4-thiazoly
- 7-Amino-3-[[[2,5-Dihydro-6-Hydroxy-2-Methyl-5-Oxo-1,2,4-Trizin-3-Yl]-Thio]Methyl]-Cephalosporanic Acid
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6α,7β(Z)]]-
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-
- Ceftisomin
- syn-7-(2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carbo xyli
- (6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Cefimx
- FR-13749
- [(6R-[6α，7β(Z)])-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct2-ene-2-carboxylie acid
- (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Ceftizoxime Ceftizoxime
- Ceftizoxime >
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-
- Ceftizoxime USP/EP/BP
- (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Ceftizoxime (1098173)
- 1,2-Benzenedicarboxylicacid,bis(8-methylbutyl)ester
- Ceftizoxime, ≥ 98.0%
- (7R)-7β-[2-(2-アミノ-4-チアゾリル)-2-(メトキシイミノ)アセチルアミノ]セファム-3-エン-4-カルボン酸
- セフィゾックス
- セフチックス
- (7R)-7-[[2-(2-アミノチアゾール-4-イル)-2-(メトキシイミノ)-1-オキソエチル]アミノ]セファム-3-エン-4-カルボン酸
- セフチソミン
- エポセリン
- (6R,7R)-7α-[2-(2-イミノ-4-チアゾリン-4-イル)-2-[(Z)-メトキシイミノ]アセチルアミノ]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- (6R,7R)-7-[(Z)-2-(2-アミノ-4-チアゾリル)-2-メトキシイミノアセチルアミノ]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- CZX【セフチゾキシム】
- セフチゾキシム
- セフチゾックス
- セフチゾオキシム
- (6R,7R)-7-[(2Z)-2-(2-イミノ-2,3-ジヒドロ-1,3-チアゾール-4-イル)-2-(メトキシイミノ)アセトアミド]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- (6R,7R)-7-[2-(2-アミノ-1,3-チアゾール-4-イル)-2-(メトキシイミノ)アセトアミド]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- セフチゾクス
- セファロスポリン類(lèi)